Said Azzoug , Fadila Chabour , Leyla Rabehi , Farida Chentli

Department of Endocrine and Metabolic diseases, Bab El Oued Hospital, Algiers, Algeria
Author    Correspondence author
International Journal of Clinical Case Reports, 2015, Vol. 5, No. 10   doi: 10.5376/ijccr.2015.05.00010
Received: 17 Dec., 2014    Accepted: 17 Jan., 2015    Published: 27 Feb., 2015

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Azzoug et al., 2015, Malignant insulinoma, International Journal of Clinical Case Reports, Vol.5, No. 10 1-3 (doi: 10.5376/ijccr.2015.05.0010)

Malignant insulinomas are rare representing 4-14% of insulinomas with poor prognosis. Diagnosis of malignancy relies on the presence of lymph node or distant metastasis. Clinical manifestations of malignant insulinomas are similar but are more severe and frequent to those of benign insulinomas characterized by clinical hypoglycemic signs with predominance of neuroglucopenic symptoms. Surgical removal of the tumor and eventually metastasis is the corn stone of the treatment, other therapeutic modalities and anti-secretion drugs are complementary treatments. In this study we report the observations of three malignant insulinomas.  

 

Malignant insulinoma; Hypoglycemia; Surgery; Anti-secretion drugs